“Looking at the lens, you see how just quite different it is from most of the multifocal presbyopia correcting IOLs that we’re used to seeing. It doesn’t have rings or transition zones in it. It has a segmented bifocal portion of the lens, which is allowing it to divide light for distance, mid and near, and give patients truly spectacle independence, maintaining quality of vision, excellent contrast sensitivity. I think most importantly in my mind as a surgeon and patient’s real lives, it has a wonderful dysphotopsia profile, a very friendly dysphotopsia profile. The ClearView 3 lens is a very easy lens to use intraoperatively. I think its haptic design lends itself to really great rotational stability and stability within the bag. Patient satisfaction is exceedingly high. I really haven’t had any patients complain about this lens, which is really quite surprising, pleasantly surprising.”
“ClearView provides high quality distance, intermediate and near vision and due to the ClearView optic being designed without concentric rings, I believe my patients have limited glare and halos at night compared to other multifocal lenses on the market. My FDA study patients still have excellent vision and are free from glasses. I see them every year and it makes me confident to recommend the ClearView to my patients today.”
“The Clearview 3 has quickly become my preferred lens for my patients seeking glasses independence. I finally have a multifocal lens that delivers both an impressive range of vision and optical quality. At first, I was skeptical of the reports of decreased glare and halos because of my experience with other lenses claiming similar things. But I am happy to report that I continue to be blown away by patient satisfaction with this lens.”
“Patients have reported high levels of satisfaction with minimal side effects. I believe the ClearView 3 will be an excellent option for refractive lens surgeons to offer their patients seeking their best vision and independence from glasses after cataract surgery. No patients in the study reported negative dysphotopsia and reported a 94% rate of spectacle independence.”
“The ClearView 3 provides a full range of vision without the nighttime glare. My patients are extremely happy with this lens.”
“Because of the great add power that the ClearView 3 lens gives you in terms of the reading portion…patients immediately are just like, oh my God! Wow.….There is a reading component that pops for that patient right away”.
“I would tell younger surgeons or surgeons who are just starting to use this technology, look for patients with low astigmatism, look for patients that have an above average sized pupil in normal light conditions.”
“The ClearView appears to have fewer positive dysphotopsias and night vision complaints compared to a standard diffractive multifocal IOL. Nearly all patients had excellent uncorrected near acuity and we did not see any loss of best spectacle corrected acuity. Overall, ClearView is a lens that is easily integrated into the arsenal of advanced technology IOLs available to the refractive cataract surgeon.”
“My initial thought was, this is a very straight lens to implant and very forgiving with excellent patient satisfaction.”
“In my own experience with ClearView, I have been very impressed with the quality and range of functional vision that patients obtain as well as their overall happiness. It performs well in low lighting and patients report excellent night driving. It is a great lens that I wouldn’t hesitate to have implanted in my own eyes.”
“This lens offers a couple of different advantages. One of which is quarter diopter steps that it has available. This enables us to be that much more accurate in our selection of a lens power for a particular patient. I would really encourage any surgeon who’s thinking about adopting this technology that it’s worth pursuing. We’ve been really happy, really excited being able to share in our patient’s excitement with how they see with this technology. I’d highly recommend it to any surgeon thinking about it. We find patients adapt very quickly to this lens. So, there’s a bit less of the concern that there’s going to be a long period of time of adaptation. In our experience it’s been very fast.”
“The precision of the ClearView 3 and how it’s developed, allows a surgeon to dial in a patient’s power needs to a quarter diopter. When all other lenses in the industry are standardized at half diopter increments, this quarter diopter increment allows me, as a surgeon, to really give the customized lens power patients need. It’s like that shoe that just doesn’t fit right. Well now, with ClearVIew 3 and Lenstec technology, we’re allowed to get that perfect fit.”
“The design and the technology of the ClearView 3 is what sets it apart, and why patients see it’s so beneficial. It’s a refractive technology, which means we’re not splitting light here…there’s minimal transition zones as opposed to the multiple on multifocal lenses. This technology translates to patients being able to read better in dim lighting, see better distance at night, and really have the best vision possible for these advanced placement lenses.”
Having used the ClearView 3 multifocal IOL for over 10 years, I have been highly impressed with the excellent visual outcomes and high level of patient satisfaction. The lens is straightforward to use, inject into the eye and position. Once in place it remains very stable. The availability in 0.25D lens power increments allows for improved refractive targeting. Over 95% of my patients implanted with the ClearView 3 reported being satisfied or highly satisfied with their unaided visual outcome for distance, intermediate and near vision under both photopic and mesopic light conditions. The incidence of troublesome dysphotopsia with the rotationally asymmetrical lens design has been very low and no patients reported any significant problems with night-time vision or driving. I have found Lenstec to be a friendly and helpful company to deal with. The ClearView 3 is an excellent lens and has remained my first choice multifocal IOL for suitable patients with under 1.5D of corneal astigmatism and pupils larger the 2.8mm.